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SciOBJECTIVES The purpose of this study was to compare the relative risk of major bleeding with left atrial appendage
(LAA) closure compared with long-term warfarin therapy.
BACKGROUND LAA closure is an alternative approach to chronic oral anticoagulation for the prevention of throm-
boembolism in patients with atrial ﬁbrillation (AF).
METHODS We conducted a pooled, patient-level analysis of the 2 randomized clinical trials that compared WATCHMAN
(Boston Scientiﬁc, Natick, Massachusetts) LAA closure with long-term warfarin therapy in AF.
RESULTS A total of 1,114 patients were included, with a median follow-up of 3.1 years. The overall rate of major
bleeding from randomization to the end of follow-up was similar between treatment groups (3.5 events vs. 3.6 events
per 100 patient-years; rate ratio [RR]: 0.96; 95% conﬁdence interval [CI]: 0.66 to 1.40; p ¼ 0.84). LAA closure
signiﬁcantly reduced bleeding >7 days post-randomization (1.8 events vs. 3.6 events per 100 patient-years; RR: 0.49;
95% CI: 0.32 to 0.75; p ¼ 0.001), with the difference emerging 6 months after randomization (1.0 events vs. 3.5 events
per 100 patient-years; RR: 0.28; 95% CI: 0.16 to 0.49; p < 0.001), when patients assigned to LAA closure were able to
discontinue adjunctive oral anticoagulation and antiplatelet therapy. The reduction in bleeding with LAA closure was
directionally consistent across all patient subgroups.
CONCLUSIONS There was no difference in the overall rate of major bleeding in patients assigned to LAA closure
compared with extended warfarin therapy over 3 years of follow-up. However, LAA closure signiﬁcantly reduced bleeding
beyond the procedural period, particularly once adjunctive pharmacotherapy was discontinued. The favorable effect of
LAA closure on long-term bleeding should be considered when selecting a stroke prevention strategy for patients with
nonvalvular AF. (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation;
NCT00129545; and Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long
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dependent oral anticoagulant
OAC = oral anticoagulant
RRR = relative risk reduction
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1926A trial ﬁbrillation (AF) is associatedwith a 4- to 5-fold increased risk ofischemic stroke after adjustment
for other risk factors (1). Oral anticoagulant
(OAC) therapy reduces this risk but increases
the risk of bleeding (2), which contributes to
underutilization and frequent discontinua-
tion (3–5). Despite the established efﬁcacy
of the non-vitamin K–antagonist oral antico-agulant agents (NOACs), the randomized clinical tri-
als of these agents excluded patients with previous
bleeding or those with conditions associated with a
high bleeding risk (6–10). Therefore, there is an un-
met clinical need for alternative therapeutic ap-
proaches that reduce thromboembolic events but are
associated with less long-term bleeding.SEE PAGE 1933The left atrial appendage (LAA) is the probable
source of most thromboembolic events in patients
with nonvalvular AF (11,12). The results of the
PROTECT-AF (WATCHMAN Left Atrial Appendage
System for Embolic Protection in Patients with Atrial
Fibrillation) and PREVAIL (Prospective Randomized
Evaluation of the Watchman LAA Closure Device In
Patients with Atrial Fibrillation Versus Long Term
Warfarin Therapy) trials demonstrated that trans-
catheter LAA closure followed by discontinuation of
long-term OAC is a safe and effective alternative to
long-term warfarin anticoagulation for the preven-
tion of stroke, systemic embolism, and cardiovascular
death in AF patients at moderate-to-high thrombo-
embolic risk (13,14). Differences in bleeding outcomes
between mechanical closure and long-term warfarin
therapy could help inform the selection of the
appropriate management strategy for stroke preven-
tion in patients with AF. The goal of this study was
to assess the relative risks of bleeding over time with
a strategy of transcatheter LAA closure compared
with long-term warfarin therapy among OAC-eligible
patients.
METHODS
PATIENT POPULATION AND STUDY PROCEDURES.
This was a pooled, patient-level analysis of the
PROTECT-AF and PREVAIL randomized clinical trials.
The study designs of these trials have been described
previously (13,15). In brief, the PROTECT-AF trialnd the LAA closure technology has been licensed to Boston Sci
rights to receive future royalties from this license.
received June 9, 2015; revised manuscript received August 25, 2randomly assigned 707 AF patients with CHADS2
(congestive heart failure, hypertension, age $75
years, diabetes mellitus, stroke) score $1 who were
eligible for long-term OAC to either LAA closure with
the WATCHMAN device (Boston Scientiﬁc, Natick,
Massachusetts) or warfarin in a 2:1 ratio; the PREVAIL
trial randomly assigned 407 OAC-eligible AF patients
with CHADS2 scores $2 (and selected patients with
CHADS2 ¼ 1 and an additional risk factor) to either
WATCHMAN LAA closure or warfarin in a 2:1 ratio.
The inclusion and exclusion criteria of the 2 trials
were otherwise similar, except that patients requiring
clopidogrel therapy at baseline were eligible for
PROTECT-AF but not PREVAIL. In both trials, pa-
tients who were randomly assigned to LAA closure
continued warfarin and aspirin for approximately
6 weeks post-procedure, when transesophageal
echocardiography was performed to conﬁrm LAA
sealing. If the LAA was adequately sealed (peridevice
leak <5 mm in diameter), patients discontinued
warfarin and were treated with aspirin and clopi-
dogrel for 6 months post-procedure, followed by
indeﬁnite aspirin therapy (Figure 1).
ENDPOINTS AND DEFINITIONS. The primary efﬁcacy
endpoint of both trials was a composite of cardio-
vascular or unexplained death, stroke, and systemic
embolism. Major bleeding was deﬁned as an adverse
event that was assigned 1 of several bleeding codes
and was adjudicated by the clinical events committee
as signiﬁcant (life-threatening or resulting in hospi-
talization, prolongation of hospitalization, substan-
tial disability, or death). CHADS2 and CHA2DS2-VASc
(congestive heart failure, hypertension, age $75
years, diabetes mellitus, stroke/transient ischemic
attack, vascular disease, age 65 to 74 years, sex
category) scores were calculated according to Gage
et al. (16) and Lip et al. (17), respectively. Modiﬁed
HAS-BLED scores were calculated according to Pisters
et al. (18), except that no points were assigned for
liver dysfunction or labile international normalized
ratio values, as these data were not systematically
collected. High baseline bleeding risk was deﬁned as a
modiﬁed HAS-BLED score $3, consistent with society
guidelines (19).
STATISTICAL ANALYSIS. Patient-level data were
pooled from the PROTECT-AF and PREVAIL trials
at 2,717 and 860 patient-years of follow-up, re-
spectively, and were analyzed using a frequentistentiﬁc, and both Mayo Clinic and Dr. Holmes have
015, accepted August 27, 2015.
FIGURE 1 Timeline of Adjunctive Pharmacotherapy in Patients Randomly Assigned to Device Therapy
From implant to 45 days, patients were treated with a combination of aspirin and warfarin, and if TEE then documented a seal (leak <5 mm),
patients were treated with a combination of aspirin and clopidogrel from 45 days to 6 months. After this period of adjunctive pharmacotherapy,
patients were treated with aspirin monotherapy (“destination therapy”). ASA ¼ aspirin; TEE ¼ transesophageal echocardiography.
TABLE 1 Baseline Characteristics of the Study Population
Treatment Arm
p Value
LAA Closure
(n ¼ 732)
Long-Term Warfarin
(n ¼ 382)
Age, yrs 72.5  8.4 73.5  8.6 0.09
Age >65 yrs 616 (84.2) 329 (86.1) 0.38
Male 508 (69.4) 274 (71.7) 0.45
Hypertension 653 (89.2) 354 (92.7) 0.07
Diabetes mellitus 204 (27.9) 113 (29.6) 0.58
Previous myocardial infarction 105 (14.3) 77 (20.2) 0.02
Previous stroke 104 (14.2) 61 (16.0) 0.43
Previous major bleeding 96 (13.1) 52 (13.6) 0.82
CHADS2 2.3  1.1 2.4  1.2 0.06
CHA2DS2-VASc 3.6  1.4 3.8  1.5 0.02
CHA2DS2-VASc $2 692 (94.9) 367 (96.8) 0.17
Modiﬁed HAS-BLED 1.9  0.9 1.9  1.0 NS
Values are mean  SD or n (%). Patients were randomized in a 2:1 fashion to either LAA closure or
long-term warfarin. The modiﬁed HAS-BLED score provided zero points for liver disease and labile
international normalized ratio.
CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke;
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age$75 years, diabetes mellitus, stroke/
transient ischemic attack, vascular disease, age 65–74 years, sex category; LAA ¼ left atrial
appendage; NS ¼ not signiﬁcant.
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1927statistical approach. The PREVAIL patients were
assessed without the informative prior. Post-hoc
landmark analyses were performed at 7 days, 45
days, and 6 months post-procedure to assess the in-
ﬂuence of procedural complications and adjunctive
pharmacotherapy on rates of bleeding. Log-rank tests
were used to compare Kaplan-Meier curves for overall
follow-up and beyond 7 days, because the propor-
tional hazards assumption was not met for these pe-
riods. Events per 100 patient-years were compared
using Poisson regression models including random
study effects. Cox proportional hazards models were
used to compare groups beyond 45 days and beyond
6 months, as the proportional hazard assumption was
met for these periods (p ¼ 0.20 and p ¼ 0.23,
respectively). Cox proportional hazards models were
used to test subgroup-by-treatment interactions. All
Cox models used a marginal models approach to ac-
count for intrastudy correlation. Categorical variables
are reported as counts (percentages), and continuous
variables are reported as the mean  SD or median
and interquartile range (IQR) where appropriate.
Statistical signiﬁcance was accepted at the 95% con-
ﬁdence level (p < 0.05).
RESULTS
A total of 1,114 patients were included in the analysis,
of which 732 and 382 were randomly assigned to de-
vice and warfarin therapy, respectively. Baseline
characteristics are summarized in Table 1. Overall, the
mean age was 72.9  8.5 years, the mean CHA2DS2-
VASc score was 3.7  1.4, and the mean modiﬁed HAS-
BLED score was 1.9  1.0. A CHA2DS2-VASc score $2
was present in 95.6% of patients, and a modiﬁed HAS-
BLED score $3 in 22.1%. The mean CHA2DS2-VASc
score was slightly higher and previous myocardial
infarction more frequent in the long-term warfarin
group (p ¼ 0.02 for both). Patients were followed for a
median of 3.1 years (IQR: 2.0 to 5.0 years). Cumulativefollow-up was 2,422 patient-years for the device
group and 1,249 patient-years for the warfarin group.
The time within therapeutic range among patients
assigned to warfarin therapy was 69%. Among pa-
tients receiving the device, the median duration of
warfarin treatment was 50 days (IQR: 43 to 57 days),
and 89.5% permanently discontinued warfarin over
the course of the trial.
BLEEDING RATES. The distribution of bleeding risk
and the observed rates of bleeding according to
treatment group are shown in Tables 2 and 3. The
bleeding rates from randomization to the end of
follow-up were similar between patients randomly
assigned to device and long-term warfarin therapy
(3.5 events vs. 3.6 events per 100 patient-years; rate
ratio (RR): 0.96; 95% CI: 0.66 to 1.40; p ¼ 0.84).
Approximately one-half of the bleeding events in the
TABLE 2 Distribution of Modiﬁed HAS-BLED Scores Among the
Patient Population
Modiﬁed
HAS-BLED Score
LAA Closure
(n ¼ 732)
Warfarin
(n ¼ 382)
0 34 (4.6) 17 (4.5)
1 220 (30.1) 123 (32.2)
2 284 (38.8) 151 (39.5)
3 124 (16.9) 66 (17.2)
4 31 (4.2) 19 (5.0)
5 0 6 (1.6)
Values are n (%). Patients were randomized in a 2:1 fashion to either LAA closure
or long-term warfarin The modiﬁed HAS-BLED score provided no points for liver
disease and labile international normalized ratio.
LAA ¼ left atrial appendage.
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1928device group (48%) occurred within the ﬁrst 7 days
after randomization, that is, during the periprocedural
period. LAA closure signiﬁcantly reduced the rate of
major bleeding compared with long-term warfarin
beyond 7 days post-randomization (1.8 events vs. 3.6
events per 100 patient-years; RR: 0.49; 95% CI: 0.32 to
0.75; p ¼ 0.001), beyond 45 days (1.3 events vs. 3.6
events per 100 patient-years; RR: 0.37; 95% CI: 0.23 to
0.60; p < 0.001); and beyond 6 months (1.0 events vs.
3.5 events per 100 patient-years; RR: 0.28; 95% CI: 0.16
to 0.49; p < 0.001). The decrease in bleeding with LAA
closure was driven by reductions in both gastrointes-
tinal bleeding and hemorrhagic stroke (Table 4).
The difference in survival free from bleeding
increased with continued follow-up (Figure 2). Land-
mark analyses across several intervals (Figures 2 and 3)
suggest that the reduction in bleeding with LAA
closure began 6 months after randomization, consis-
tent with when patients in the device group could
discontinue adjunctive pharmacotherapy (warfarin
and aspirin followed by dual antiplatelet therapy).
SUBGROUP ANALYSES. The relationships between
clinical characteristics and bleeding beyond 6 months
post-randomization are shown in Table 5. LAA closureTABLE 3 Observed Rates of Major Bleeding Over Time According to T
LAA Closure
(n ¼ 732)
Bleeding Rate
(n events/N at risk)
Event Rate/100 pt-yrs
(n events/pt-years)
Ble
(n ev
Overall 10.8 (79/732) 3.5 (79/2,268) 11.
Post-procedural 5.9 (40/682) 1.8 (40/2,255) 11.
Destination therapy 3.2 (19/601) 1.0 (19/1,958) 9.
Values are % (n/N). The overall period was deﬁned as after randomization to the end of f
up, thereby isolating nonprocedural related bleeding events; and destination therapy pe
were eligible to receive aspirin alone. Patients were randomized in a 2:1 fashion to eithe
LAA ¼ left atrial appendage; Pt-yrs ¼ patient-years.signiﬁcantly reduced bleeding irrespective of age,
sex, baseline bleeding risk, or thromboembolic risk
score. The relative magnitude of beneﬁt was signiﬁ-
cantly greater in females, patients #75 years of age,
and those with modiﬁed HAS-BLED scores <3.
DISCUSSION
The main ﬁndings of this study are that among OAC-
eligible patients with AF: 1) the overall rate of major
bleeding over a median follow-up of 3 years was
similar with a strategy of LAA closure compared with
long-term warfarin; and 2) LAA closure led to a sig-
niﬁcant and substantial reduction in major bleeding
once the required period of adjunctive anticoagulant
and dual antiplatelet pharmacotherapy for the device
was completed. Furthermore, LAA closure signiﬁ-
cantly reduced nonprocedural bleeding across risk
and age strata. These ﬁndings have important impli-
cations for the selection of a management strategy for
stroke prevention in patients with nonvalvular AF.
Although the clinical efﬁcacy of OAC is well
established, concerns about long-term bleeding are a
major driver of OAC prescribing patterns as well as
treatment discontinuation in patients who have
already initiated therapy (3–5). The current analysis
demonstrates that, although the overall rate of
bleeding was similar between groups at a median
follow-up duration of 3 years beyond the immediate
procedural period, the risk of bleeding was substan-
tially lower after LAA closure than with long-term
warfarin therapy. Indeed, beyond 6 months after the
procedure, when all adjunctive pharmacotherapy
other than aspirin could be discontinued, LAA closure
provided a 72% relative risk reduction (RRR) in major
bleeds. This reduction was driven mainly by gastro-
intestinal bleeding and to a lesser extent by hemor-
rhagic stroke. Although the NOACs also reduce
hemorrhagic stroke compared with warfarin, their
use is associated with greater or similar rates ofreatment Group
Long-Term Warfarin
(n ¼ 382)
Rate Ratio (95% CI) p Value
eding Rate
ents/N at risk)
Event Rate/100 pt-yrs
(n events/pt-years)
3 (43/382) 3.6 (43/1,187) 0.96 (0.66–1.40) 0.84
3 (43/381) 3.6 (43/1,180) 0.49 (0.32–0.75) 0.001
7 (35/360) 3.5 (35/1,004) 0.28 (0.16–0.49) <0.001
ollow-up; post-procedural period as >7 days after randomization to the end of follow-
riod as beyond 180 days post-randomization, when patients assigned to LAA closure
r LAA closure or long-term warfarin.
FIGURE 2 Kaplan-Meier Curves for Major Bleeding
(A) Freedom from ﬁrst major bleed from randomization to the end of fo
the end of follow-up (the post-procedural period) (p ¼ 0.002). (C) Fre
(hazard ratio: 0.38; 95% conﬁdence interval: 0.33 to 0.44; p < 0.001).
(hazard ratio: 0.28; 95% conﬁdence interval: 0.23 to 0.35; p < 0.001).
TABLE 4 Types and Frequencies of Major Bleeding Events That
Occurred After the Period of Adjunctive Pharmacotherapy (OAC
and DAPT) in the Device Group (>6 Months Post-Randomization)
LAA Closure
(n ¼ 732)
Warfarin
(n ¼ 382) p Value
Gastrointestinal bleeding 10 (1.4) 21 (5.5) <0.001
Epistaxis 1 (0.1) 1 (0.3) 1.0
Hematuria 0 (0) 2 (0.5) 0.12
Hemorrhagic stroke 2 (0.3) 7 (1.8) 0.01
Cranial bleed 3 (0.4) 1 (0.3) 1.0
Anemia requiring transfusion 2 (0.3) 1 (0.3) 1.0
Major bleed requiring transfusion 1 (0.1) 1 (0.3) 1.0
Other bleeding 0 (0) 1 (0.3) 0.35
Values are n (%). Note that patients were randomly assigned to LAA closure or
warfarin therapy in a 2:1 fashion.
DAPT ¼ dual antiplatelet therapy; LAA ¼ left atrial appendage; OAC ¼ oral
anticoagulation.
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1929gastrointestinal bleeding (6,7,9,10). Although LAA
closure is associated with a signiﬁcant procedural
hazard, there is an important practical distinction
between bleeding that occurs at the time of the device
implantation (e.g., pericardial effusion or groin he-
matoma) and nonprocedural, anticoagulation-related
bleeding: the former occurs in the hospital setting
where medical care is immediately available, whereas
the latter may occur when prompt care is not rapidly
accessible.
The reduction in bleeding with LAA closure
compared with chronic warfarin was directionally
consistent among all patient subgroups examined.
Paradoxically, we observed a particular advantage for
LAA closure in patients with lower HAS-BLED scores,
possibly because the bleeding risk score also predicts
bleeding in patients who are not anticoagulated (18).
Patients with high HAS-BLED scores may, therefore,llow-up (p ¼ 0.97). (B) Freedom from ﬁrst major bleed from 8 days post-randomization to
edom from ﬁrst major bleed from 45 days post-randomization to the end of follow-up)
(D) Freedom from ﬁrst major bleed from 6 months post-randomization to the end of follow-up
FIGURE 3 Landmark Analysis of the Freedom From Major Bleeding Over 3 Intervals of
Follow-Up
3 intervals: from randomization to day 7, representing the periprocedural period for patients
randomly assigned to left atrial appendage closure; 8 days to 6 months post-
randomization, during which device-treated patients received warfarin and aspirin followed
by dual antiplatelet therapy; and beyond 6 months, when device-treated patients were
eligible to receive aspirin alone.
TABLE 5 Major Blee
Age #75 yrs
Age >75 yrs
CHA2DS2-VASc #4
CHA2DS2-VASc >4
Modiﬁed HAS-BLED <3
Modiﬁed HAS-BLED $3
No history of
TIA/stroke
History of TIA/stroke
Female
Male
Values are % (n/N) unless
LAA ¼ left atrial append
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1930face a continued risk of bleeding even after discon-
tinuation of post-procedural anticoagulation, dimin-
ishing the absolute beneﬁt of LAA closure. Even so,
the absolute and relative reductions in bleeding >6
months after LAA closure were substantial and clini-
cally relevant in patients at high bleeding risk (RRR:
45%; absolute risk reduction: 6.8%) and in those
$75 years of age (RRR: 57%; absolute risk reduction:
6.5%). These observations suggest that the long-term
safety beneﬁt of LAA closure over warfarin applies
across the spectrum of bleeding risk.ds Beyond 6 Months Post-Randomization According to Subgroup
LAA
Closure Warfarin
Hazard Ratio
(95% Conﬁdence
Interval)
p
Value
p
Interaction
1.4 (6/436) 7.8 (17/217) 0.17 (0.147–0.196) <0.001 0.005
4.4 (13/296) 10.9 (18/165) 0.43 (0.264–0.701) 0.001
1.8 (10/551) 8.5 (22/258) 0.21 (0.138–0.321) <0.001 0.28
5.1 (9/178) 10.7 (13/121) 0.47 (0.161–1.378) 0.17
1.4 (8/561) 7.9 (23/291) 0.17 (0.173–0.174) <0.001 0.001
6.4 (11/171) 13.2 (12/91) 0.55 (0.282–1.070) 0.078
2.3 (13/570) 8.9 (26/292) 0.26 (0.216–0.305) <0.001 0.67
3.7 (6/162) 10.0 (9/90) 0.35 (0.102–1.225) 0.10
1.8 (4/224) 12.0 (13/108) 0.17 (0.074–0.369) <0.001 0.02
3.0 (15/508) 8.0 (22/274) 0.35 (0.320–0.393) <0.001
otherwise speciﬁed.
age; TIA ¼ transient ischemic attack.In this patient-level, pooled analysis of the ran-
domized clinical trial experience of the WATCHMAN
device, procedure-related events were the major
driver of bleeding in the device group, highlighting
the importance of procedural safety in determining
the overall risk to beneﬁt ratio of LAA closure as an
alternative management strategy for stroke preven-
tion in patients with AF. However, the event curves
continued to diverge over time, consistent with
the increased hazard of bleeding with warfarin
compared to aspirin alone even in OAC-eligible pa-
tients (20). The risk of major bleeding is expected
to persist or increase in patients treated with chronic
OAC as they age. Therefore, although the overall
major bleeding rates were similar between LAA
closure and chronic warfarin therapy, improved sa-
fety (13) and longer follow-up seems likely to favor
LAA closure. Our ﬁndings may not be extrapolated to
other methods of LAA closure, which have been
associated with higher rates of procedural bleeding
or other procedure-related complications (21,22), or
to anticoagulation with agents other than warfarin,
such as the NOACs.
The adjunctive pharmacotherapy afterWATCHMAN
implantation used in the current trials was empirical.
The results of this analysis suggest that the risk of
bleeding during the period of adjunctive pharmaco-
therapy in the device arm was similar to that in
the warfarin arm (Figure 2), consistent with previous
observations that the risk of bleeding increases when
aspirin is given concurrently with warfarin and is
similar with dual antiplatelet therapy compared with
warfarin alone (19,23). Whether a shorter period of
post-procedural dual antiplatelet therapy or warfarin
could reduce nonprocedural bleeding and improve the
post-procedural risk proﬁle of LAA closure deserves
further evaluation, particularly in patients at very high
bleeding risk (24).
STUDY LIMITATIONS. Major bleeding was not a pro-
spectively deﬁned endpoint in the clinical trial pro-
tocols. However, the bleeding events included in this
analysis were all site-reported and adjudicated by a
clinical events committee. The reduction in bleeding
with LAA closure compared with continued warfarin
therapy may be underestimated, as it does not ac-
count for patients in the warfarin group who dis-
continued the drug. We used a modiﬁed HAS-BLED
score, because certain characteristics included in the
originally described score (18) were not systematically
collected. Although the prognostic strength of this
modiﬁed score has not been validated, it was associ-
ated with bleeding rates during follow-up. Slight dif-
ferences in clinical characteristics in the randomized
PERSPECTIVES
WHAT IS KNOWN? LAA closure with the WATCHMAN device
followed by discontinuation of long-term OAC is an effective
alternative to long-term warfarin anticoagulation for the pre-
vention of stroke, systemic embolism, and cardiovascular death
in AF patients at moderate-to-high thromboembolic risk.
WHAT IS NEW? Although there was no difference in the
overall rate of major bleeding over 3 years of follow-up in
patients assigned to LAA closure compared with extended
warfarin therapy, LAA closure signiﬁcantly reduced bleeding
beyond the immediate periprocedural period, and particularly
beyond 6 months, when patients assigned to device therapy
could discontinue adjunctive anticoagulation and dual anti-
platelet therapy. This bleeding beneﬁt continued to accrue
over time, and was consistent across baseline bleeding risk
strata.
WHAT IS NEXT? Whether a shorter period of post-procedural
warfarin or dual antiplatelet therapy could reduce nonprocedural
bleeding and improve the post-procedural risk proﬁle of LAA
closure deserves further evaluation.
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1931arms, likely due to chance, may have inﬂuenced
treatment effects. These analyses were post-hoc and
are therefore exploratory and hypothesis-generating.
Finally, this analysis does not address the compara-
tive risk of bleeding with NOACs, which have been
associated with similar (6) or lower rates of all-cause
bleeding (7,9,10) compared with warfarin.
CONCLUSIONS
In this pooled, patient-level analysis of the
WATCHMAN randomized clinical trial experience,
there was no difference in the overall rate of major
bleeding (procedural and nonprocedural) over 3 years
of follow-up in patients assigned to LAA closure
compared with extended warfarin therapy. However,
LAA closure signiﬁcantly reduced the rate of major
bleeding beyond the periprocedural period, particu-
larly beyond 6 months after randomization, when pa-
tients assigned to device therapy could discontinue
adjunctive anticoagulation and dual antiplatelet
therapy. LAA closure decreased bleeding beyond the
procedural period in older and younger patients, those
with high and low HAS-BLED scores, and in males and
females. Society guidelines recommend that antith-
rombotic therapy should be individualized on the ba-
sis of shared decision-making after discussion of the
absolute and relative risks of stroke and bleeding
(Class I, Level of Evidence: C) (25). The effect of LAA
closure on long-term bleeding should be integrated
into this discussion when selecting a management
strategy for stroke prevention in AF patients.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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